Decreased cerebral blood flow, insulin resistance, inhibition of GLUT (Glucose) transporters and glycolytic enzymes, and amyloid-stimulated PDH phosphorylation all contribute to decreased glucose metabolism in clinical AD and transgenic models [14,15,16,17]. The gene discussed is PDP1; the disease is Alzheimer disease.